The Evaluation of Danofloxacin in the Therapy of Pneumonia Associated With Pasteurella Species in Young Calves

A Summary


  • H. Barthel Animal Health Division, Pfizer, Inc, Karlsruhe, Germany
  • C. J. Giles Central Research Division, Pfizer, Inc, Sandwich, U.K.
  • B. Roelants Animal Health Division, Pfizer, Inc, Brussels, Belgium
  • D. Stellingwerf Animal Health Division, Pfizer, Inc, Rotterdam, Netherlands
  • C. Thomasson European Clinical Development, Pfizer, Inc, Orsay, France
  • S. T. Tolling Animal Health Group, Pfizer, Inc, New York, U.S.A.



Acute pneumoni, Pasteurella spp., lung lesions, management factors, fluoroquinolone antimicrobial danofloxacin


Acute pneumonia is an economically important disease afflicting young cattle world-wide. The disease develops as a complex interaction and the aetiology of any outbreak is often multifactorial (1). Pasteurella spp. are the most important bacteria involved causing fibrinous bronchopneumonia (2, 3), but more frequently they increase the severity of lung lesions inflicted by viruses and/or mycoplasmas. Transport, housing and mixing of animals are management factors contributing to outbreaks of acute pneumonia. This paper summarizes the results of seven studies conducted in Europe in which the efficacy of the fluoroquinolone antimicrobial danofloxacin* against naturally occurring outbreaks of acute pneumonia in calves was evaluated in comparison with trimethoprim/sulpha.






Respiratory Disease